Home › Funds › Sofinnova Investments, Inc. › INBX
Sofinnova Investments, Inc. position in INBX
INHIBRX BIOSCIENCES INC COM · Health Care
Sofinnova Investments, Inc. reported holding 303,103 shares of INBX (INHIBRX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$28.7M, representing 1.53% of its reported portfolio and ranking #24 among its reported holdings. Sofinnova Investments, Inc. has disclosed INBX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s INBX position evolved
Sofinnova Investments, Inc. first disclosed a stake in INBX in Q3 2023 at 743,294 shares (US$13.6M). The position peaked in Q1 2024 at 1,302,645 shares, worth US$45.5M. Across 12 filings, Sofinnova Investments, Inc. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 303,103 shares valued at US$28.7M — a reduction of -102,926 shares quarter over quarter.. Notable position changes include a 69% increase in Q1 2024, a 64% trim in Q2 2024 (shares rose 11% over the following quarter), a 38% trim in Q3 2025 (shares rose 135% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 743.29K | $13.64M | New |
| Q4 2023 | 772.96K | $29.37M | Add |
| Q1 2024 | 1.30M | $45.54M | Add |
| Q2 2024 | 463.31K | $6.57M | Reduce |
| Q3 2024 | 536.07K | $8.39M | Add |
| Q4 2024 | 527.19K | $8.12M | Reduce |
| Q1 2025 | 697.92K | $9.76M | Add |
| Q2 2025 | 708.68K | $10.11M | Add |
| Q3 2025 | 440.09K | $14.82M | Reduce |
| Q4 2025 | 454.66K | $35.92M | Add |
| Q1 2026 | 406.03K | $27.30M | Reduce |
| Q2 2026 | 303.10K | $28.72M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC COM) is a Health Care company. 43 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Sanofi (US$109.7M), Schonfeld Strategic Advisors LLC (US$66.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.30M sh · $122.96M · Q2 2026
- Sanofi 1.16M sh · $109.71M · Q2 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- PFM Health Sciences, LP 308.38K sh · $29.22M · Q2 2026
- Parkman Healthcare Partners LLC 256.95K sh · $24.35M · Q2 2026
- First Turn Management, LLC 164.78K sh · $15.61M · Q2 2026
- Western Standard LLC 47.00K sh · $4.45M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held INBX?
Sofinnova Investments, Inc. has disclosed INBX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Sofinnova Investments, Inc.'s current position in INBX?
As of Q2 2026, Sofinnova Investments, Inc. holds 303.10K shares of INBX (INHIBRX BIOSCIENCES INC COM), valued at $28.72M, representing 1.53% of its reported portfolio and ranking #24.
Has Sofinnova Investments, Inc. been buying or selling INBX?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. reduced its position in INBX. The position peaked in Q1 2024 at 1.30M shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.